What's Happening?
Stipple Bio and Lonza have entered into a multi-target licensing agreement aimed at developing next-generation precision oncology antibody-drug conjugate (ADC) therapies. Stipple Bio will utilize its Pointillist Platform to identify tumor-specific cell
surface epitopes, which are crucial for creating high therapeutic index medicines that minimize on-target/off-tumor toxicity. The agreement grants Stipple Bio access to Lonza’s ADC technology platform, including GlycoConnect antibody conjugation technology, HydraSpace® polar spacer technology, and a toxSYN® linker payload. Lonza will receive upfront, clinical, regulatory, and commercial milestone payments, along with royalties on net sales of resulting products. Lonza is tasked with manufacturing components related to its proprietary technologies, while Stipple Bio will handle research and development, manufacturing, and commercialization of the ADCs.
Why It's Important?
This collaboration is significant as it combines Stipple Bio’s innovative epitope discovery capabilities with Lonza’s established bioconjugation platforms and scalable manufacturing capabilities. The partnership aims to advance the field of ADCs, which are becoming a core pillar of cancer treatment due to their ability to deliver targeted therapies with reduced off-target effects. The development of more precise and effective ADC programs could lead to better tolerated cancer treatments, potentially improving patient outcomes and expanding therapeutic options in oncology. The financial and technological support from Lonza could accelerate Stipple Bio’s efforts to bring these advanced therapies to market.
